# US 2010/0136654 A1 · Method for transcription-degradation dual regulation for protein by antibiotic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136654 A1
- Document ID: US20100136654A1
- Status: Published application
- Kind: A1
- Application number: 12/531,110
- Filed: 2008-03-14
- Published: 2010-06-03
- Earliest claimed: 2007-03-14
- Assignees: Japan Science and Technology Agency
- Inventors: Yoshihiro Miwa
- Web page: https://patentgrep.com/patent/US20100136654A1

## CPC

- C12N 15/635: {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
- C07K 14/4703: {Inhibitors; Suppressors}
- C12N 9/00: Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K 2319/95: containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
- C12N 2799/04: in vivo
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2800/40: Systems of functionally co-operating vectors
- C12N 2830/003: tet inducible
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides an expression vector, containing expressibly (a) a polynucleotide encoding a fusion protein of a mutant of a repressor protein, which binds to an antibiotic, and a target protein, and (b) a polynucleotide encoding a protein controlling the transcription of the polynucleotide in (a), the transcription of the polynucleotide in (a) and the degradation of said fusion protein, which is the expression product of the polynucleotide in (a), being controlled inside a cell by the presence or absence of an antibiotic inside the cell.

## Claims

### Claim 1

A gene expression control composition for controlling, using a site-specific recombination enzyme, the expression of a target gene inside a cell by the presence or absence of an antibiotic in the cell into which an expression vector containing expressibly the target gene between and/or downstream of recombination sequences has been introduced, comprising:
(a) an expression vector containing expressibly a polynucleotide encoding a fusion protein of a mutant of a repressor protein, which binds to an antibiotic, and a recombination enzyme, and
(b) an expression vector containing expressibly a polynucleotide encoding a protein for controlling the transcription of the polynucleotide in (a).

### Claim 2 (depends on 1)

The composition according to claim 1, wherein said recombination enzyme is at least one protein selected from the group consisting of:
(a) Cre recombinase;
(b) FLP recombinase;
(c) phage phi 13 integrase;
(d) phage R4 integrase;
(e) phage TP901-1 integrase;
(f) phage λ (lambda) integrase;
(g) phage HK022 integrase;
(h) β (beta) recombinase;
(i) R recombinase;
(j) γδ (gamma delta) resolvase;
(k) Dre recombinase;
(l) phi Rv1 integrase;
(m) Int;
(n) IHF;
(o) Xis;
(p) Fis;
(q) Hin;
(r) Gin;
(s) Cin;
(t) Th3 resolvase;
(u) TndX;
(v) XerC; and
(w) XerD.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein said recombination sequence contains one or more recombination sequences selected from the group consisting of:
(a) loxP;
(b) frt;
(c) attB/attP;
(d) six;
(e) RS;
(f) res;
(g) rox;
(h) psi;
(i) dif;
(j) cer; and
(k) mutants, variants, and derivatives of the recombination sequence from (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), which have retained the capability of provoking recombination.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein said recombination enzyme is Cre recombinase and said recombination sequence is the loxP sequence.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein said target gene is a transcription factor.

### Claim 6 (depends on 5)

The composition according to claim 5, wherein said transcription factor is any of Oct3/4, Klf4, Sox2 or c-Myc gene.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein said polynucleotide in (b) encodes a protein that binds to the transcription control region of said polynucleotide in (a) and enhances the transcription of said polynucleotide, said protein being able to bind to said transcription control region only when bound to said antibiotic.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein said fusion protein, which is the expression product of said polynucleotide in (a), is degraded when not bound to said antibiotic inside said cell.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein said antibiotic is a tetracycline-type antibiotic.

### Claim 10 (depends on 9)

The composition according to claim 9, wherein said tetracycline-type antibiotic is tetracycline, or, doxycycline, oxytetracycline, chlortetracycline or anhydrotetracycline, which are derivatives thereof.

### Claim 11 (depends on 1)

The composition according to claim 1, wherein said mutant of the repressor protein is a mutant of a tetracycline repressor protein.

### Claim 12 (depends on 11)

The composition according to claim 11, wherein said mutant of the tetracycline repressor protein has an amino acid sequence comprising at least one amino acid residue substituted in the amino acid sequence of a wild-type tetracycline repressor protein.

### Claim 13 (depends on 12)

The composition according to claim 12, wherein said substitution of amino acid residue is present at least any two sites among the aspartic acid at position 95, the leucine at position 101 and the glycine at position 102 of the amino acid sequence of the wild-type tetracycline repressor protein.

### Claim 14

A gene expression control kit for controlling, using a site-specific recombination enzyme, the expression of a target gene inside a cell by the presence or absence of an antibiotic in the cell into which an expression vector containing expressibly the target gene between and/or downstream of recombination sequences has been introduced, comprising
(a) an expression vector containing expressibly a polynucleotide encoding a fusion protein of a mutant of a repressor protein, which binds to an antibiotic, and a recombination enzyme, and
(b) an expression vector containing expressibly a polynucleotide encoding a protein for controlling the transcription of the polynucleotide in (a).

### Claim 15 (depends on 14)

The kit according to claim 14, wherein said recombination enzyme is at least one protein selected from the group consisting of:
(a) Cre recombinase;
(b) FLP recombinase;
(c) phage phi 13 integrase;
(d) phage R4 integrase;
(e) phage TP901-1 integrase;
(f) phage λ (lambda) integrase;
(g) phage HK022 integrase;
(h) β (beta) recombinase;
(i) R recombinase;
(j) γδ (gamma delta) resolvase;
(k) Dre recombinase;
(l) phi Rv1 integrase;
(m) Int;
(n) IHF;
(o) Xis;
(p) Fis;
(q) Hin;
(r) Gin;
(s) Cin;
(t) Th3 resolvase;
(u) TndX;
(v) XerC; and
(w) XerD.

### Claim 16 (depends on 14)

The kit according to claim 14, wherein said recombination sequence contains one or more recombination sequences selected from the group consisting of:
(a) loxP;
(b) frt;
(c) attB/attP;
(d) six;
(e) RS;
(f) res;
(g) rox;
(h) psi;
(i) dif;
(j) cer; and
(k) mutants, variants, and derivatives of the recombination sequence from (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), which have retained the capability of provoking recombination.

### Claim 17 (depends on 14)

The kit according to any of claim 14, wherein said recombination enzyme is Cre recombinase and said recombination sequence is the loxP sequence.

### Claim 18 (depends on 14)

The kit according to any of claim 14, wherein said target gene is a transcription factor.

### Claim 19

A gene expression control system for controlling, using a site-specific recombination enzyme, the expression of a target gene inside a cell by the presence or absence of an antibiotic, comprising
(a) a cell
(b) an expression vector that is introduced into the interior of said cell, and contains expressibly a polynucleotide encoding a fusion protein of a mutant of a repressor protein, which binds to an antibiotic, and a recombination enzyme,
(c) an expression vector that is introduced into the interior of said cell, and contains expressibly a polynucleotide encoding a protein for controlling the transcription of the polynucleotide in (b),
(d) an expression vector that is introduced into the interior of said cell, and contains expressibly a target gene between and/or downstream of recombination sequences, and
(e) an antibiotic to be introduced into the interior of said cell,
the transcription of the polynucleotide in (b) and the degradation of said fusion protein, which is the expression product of the polynucleotide in (b), being controlled inside the cell by the presence or absence of the antibiotic, and the expression of said target gene being controlled by the expressed amount of said fusion protein.

### Claim 20 (depends on 19)

The system according to claim 19, wherein said recombination enzyme is at least one protein selected from the group consisting of:
(a) Cre recombinase;
(b) FLP recombinase;
(c) phage phi 13 integrase;
(d) phage R4 integrase;
(e) phage TP901-1 integrase;
(f) phage λ (lambda) integrase;
(g) phage HK022 integrase;
(h) β (beta) recombinase;
(i) R recombinase;
(j) γδ (gamma delta) resolvase;
(k) Dre recombinase;
(l) phi Rv1 integrase;
(m) Int;
(n) IHF;
(o) Xis;
(p) Fis;
(q) Hin;
(r) Gin;
(s) Cin;
(t) Th3 resolvase;
(u) TndX;
(v) XerC; and
(w) XerD.

### Claim 21 (depends on 19)

The system according to claim 19, wherein said recombination sequence contains one or more recombination sequences selected from the group consisting of:
(a) loxP;
(b) frt;
(c) attB/attP;
(d) six;
(e) RS;
(f) res;
(g) rox;
(h) psi;
(i) dif;
(j) cer; and
(k) mutants, variants, and derivatives of the recombination sequence from (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), which have retained the capability of provoking recombination.

### Claim 22 (depends on 19)

The system according to claim 19, wherein said recombination enzyme is Cre recombinase and said recombination sequence is the loxP sequence.

### Claim 23 (depends on 19)

The system according to claim 19, wherein said target gene is a transcription factor.

### Claim 24

A gene expression control method for controlling, using a site-specific recombination enzyme, the expression of a target gene inside a cell by the presence or absence of an antibiotic, comprising the step of expressing under the presence or under the absence of an antibiotic inside said cell,
(a) an expression vector containing expressibly a polynucleotide encoding a fusion protein of a mutant of a repressor protein, which binds to an antibiotic, and a recombination enzyme,
(b) an expression vector containing expressibly a polynucleotide encoding a protein for controlling the transcription of the polynucleotide in (a), and
(c) an expression vector containing expressibly a target gene between and/or downstream of recombination sequences.

### Claim 25 (depends on 24)

The method according to claim 24, wherein said recombination enzyme is at least one protein selected from the group consisting of:
(a) Cre recombinase;
(b) FLP recombinase;
(c) phage phi 13 integrase;
(d) phage R4 integrase;
(e) phage TP901-1 integrase;
(f) phage λ (lambda) integrase;
(g) phage HK022 integrase;
(h) β (beta) recombinase;
(i) R recombinase;
(j) γδ (gamma delta) resolvase;
(k) Dre recombinase;
(l) phi Rv1 integrase
(m) Int;
(n) IHF;
(o) Xis;
(p) Fis;
(q) Hin;
(r) Gin;
(s) Cin;
(t) Th3 resolvase;
(u) TndX;
(v) XerC; and
(w) XerD.

### Claim 26 (depends on 24)

The method according to claim 24, wherein said recombination sequence contains one or more recombination sequences selected from the group consisting of:
(a) loxP;
(b) frt;
(c) attB/attP;
(d) six;
(e) RS;
(f) res;
(g) rox;
(h) psi;
(i) dif;
(j) cer; and
(k) mutants, variants, and derivatives of the recombination sequence from (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), which have retained the capability of provoking recombination.

### Claim 27 (depends on 24)

The method according to claim 24, wherein said recombination enzyme is Cre recombinase and the recombination sequence is the loxP sequence.

### Claim 28 (depends on 24)

The method according to claim 24, wherein said target gene is a transcription factor.
